Patents by Inventor Marianne Lemeur

Marianne Lemeur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transgenic animal whose expression of the opiate receptors is modified
    Patent number: 6632977
    Abstract: The invention concerns the use of a non-human transgenic mammal whose expression of a gene coding for an opiate receptor is modified, particularly in the nerve tissues with respect to a normal expression, in particular in the nerve tissues, for producing a medicine for the treatment of pathological conditions involving opiate receptors, in particular severe acute or chronic pains, drug addiction or the prevention or the treatment of transplant rejections.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: October 14, 2003
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Brigitte Kieffer, Hans W. D. Matthes, Frederic Herve Simonin, Andree Dierich, Marianne Lemeur
  • Genetically engineered mice containing alterations in the genes encoding retinoic acid receptor proteins
    Patent number: 6486381
    Abstract: The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, to mice heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptors, or the normal expression thereof, is desirable.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: November 26, 2002
    Assignees: Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis Pasteur, Bristol Myers Squibb Company
    Inventors: Pierre Chambon, Thomas Lufkin, David Lohnes, Manuel Mark, Andree Dierich, Philippe Gorry, Philippe Kastner, Marianne Lemeur, Cathy Mendelsohn
  • TRANSGENIC ANIMAL WHOSE EXPRESSION OF THE OPIATE RECEPTORS IS MODIFIED
    Publication number: 20010047519
    Abstract: The invention concerns the use of a non-human transgenic mammal whose expression of a gene coding for an opiate receptor is modified, particularly in the nerve tissues with respect to a normal expression, in particular in the nerve tissues, for producing a medicine for the treatment of pathological conditions involving opiate receptors, in particular severe acute or chronic pains, drug addiction or the prevention or the treatment of transplant rejections.
    Type: Application
    Filed: March 11, 1999
    Publication date: November 29, 2001
    Inventors: BRIGITTE KIEFFER, HANS W.D. MATTHES, FREDERIC HERVE SIMONIN, ANDREE DIERICH, MARIANNE LEMEUR
  • Genetically engineered mice containing alterations in the genes encoding retinoic acid receptor proteins
    Patent number: 6031149
    Abstract: The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, to mice heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptors, or the normal expression thereof, is desirable.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: February 29, 2000
    Assignees: Institut National De La Sante Et De La Recherche Medicale, Centre National De La Recherche Scientifique, Universite Louis Pasteur, E.R. Squibb & Sons, Inc.
    Inventors: Pierre Chambon, Thomas Lufkin, David Lohnes, Manuel Mark, Andree Dierich, Philippe Gorry, Philippe Kastner, Marianne Lemeur, Cathy Mendelsohn
  • Genetically engineered mice and cell lines containing alterations in the genes encoding retinoic acid receptor and retinoid X receptor proteins
    Patent number: 6030794
    Abstract: The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, mice which are heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptor(s), or the normal expression thereof, is desirable.
    Type: Grant
    Filed: June 27, 1995
    Date of Patent: February 29, 2000
    Assignees: Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis Pasteur, E. R. Squibb & Sons, Inc.
    Inventors: Pierre Chambon, Thomas Lufkin, David Lohnes, Manuel Mark, Andree Dierich, Philippe Gorry, Philippe Kastner, Marianne Lemeur, Cathy Mendelsohn